Seres Therapeutics, Inc.
MCRB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001609809
In the last 90 days, Seres Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 35 institutions reported holding it in 13F filings for Q2 2026, worth $17.9M in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Seres Therapeutics, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 32 | 36 | +4 |
| Shares | 2.13M | 2.44M | +315.7K (+14.9%) |
| Value | $40.9M | $36.4M | −$4.53M (−11.1%) |
New holders (9)
Institutions that held Seres Therapeutics, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 179,929 | $2.68M | 0.00% |
| 683 Capital Management, LLC | 52,314 | $778.4K | 0.06% |
| Two Sigma Investments, LP | 25,749 | $383.1K | 0.00% |
| American Century Companies Inc | 16,271 | $242.1K | 0.00% |
| Omers Administration Corp | 14,400 | $214.3K | 0.00% |
| Goldman Sachs Group Inc | 14,340 | $213.4K | 0.00% |
| ExodusPoint Capital Management, LP | 12,737 | $189.5K | 0.00% |
| Rachor Investment Advisory Services, LLC | 1,477 | $22.0K | 0.01% |
| Allworth Financial LP | 4 | $60 | 0.00% |
Sold out (5)
Institutions that held Seres Therapeutics, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| J. Goldman & Co LP | 27,000 | $519.5K |
| Citigroup Inc | 2,621 | $50.4K |
| JPMorgan Chase & Co | 65 | $1.25K |
| US Bancorp | 12 | $231 |
| Federation des caisses Desjardins du Quebec | 3 | $58 |